Drug intelligence / Profile preview

Totipro

Development stage: Unknown
Lead developer: Glac Biotech
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Totipro (益萃質) is a postbiotic ingredient line developed by GLAC Biotech Co., Ltd. (豐華生物科技). It consists of non-viable microbial products, including metabolites and cell components derived from fermented probiotic strains. Unlike live probiotics, Totipro postbiotics are heat-stable and can be incorporated into various functional food and dietary supplement formats such as tablets, lozenges, and beverages. The product line includes specific formulations like PE0401, which contains metabolites from four probiotic strains (*Lactobacillus plantarum*, *Lactobacillus salivarius*, *Bifidobacterium longum subsp. infantis*, and *Lactobacillus acidophilus*) to support gut microbiota balance and immune function, and PE0301, which targets oral health and upper digestive support, including the inhibition of oral pathogens and *Helicobacter pylori*.

Brand names: Totipro益萃質
Other names: Totipro postbiotics

Beyond the preview

Go deeper on Totipro.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Totipro.

Explore the full profile